[
  {
    "ts": null,
    "headline": "Jim Cramer Says Novo Nordisk A/S (NVO) Can’t Exceed Eli Lilly",
    "summary": "We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks. In his second appearance on Squawk on the Street after the Fed’s interest rate cut, Jim Cramer had […]",
    "url": "https://finnhub.io/api/news?id=d4ef83561a3d93b634f97e1dba7e549385b8dc422631aaa982b4c3a6de606e6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735128732,
      "headline": "Jim Cramer Says Novo Nordisk A/S (NVO) Can’t Exceed Eli Lilly",
      "id": 132144081,
      "image": "https://s.yimg.com/ny/api/res/1.2/Qtw2rnxhgzGJSiq9V2dNrA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/8ee01456c2860ad756980e44c064cbb6",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks. In his second appearance on Squawk on the Street after the Fed’s interest rate cut, Jim Cramer had […]",
      "url": "https://finnhub.io/api/news?id=d4ef83561a3d93b634f97e1dba7e549385b8dc422631aaa982b4c3a6de606e6d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Co (LLY) Is Among Billionaire Coleman’s Top Picks",
    "summary": "We recently compiled a list of the Tech Billionaire Chase Coleman’s Top 10 Stock Picks. In this article, we are going to take a look at where Eli Lilly and Co (NYSE:LLY) stands against the other top stock picks of Tech Billionaire Chase Coleman. “Tiger cub” Chase Coleman continues to shape the investment landscape with […]",
    "url": "https://finnhub.io/api/news?id=263724c2fcf91be94375f3245aca3d38b2bb391a5984eab65cde89aec8b9a17c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735127590,
      "headline": "Eli Lilly and Co (LLY) Is Among Billionaire Coleman’s Top Picks",
      "id": 132144083,
      "image": "https://media.zenfs.com/en/insidermonkey.com/93116baf3cdc210f0506241a438c0e80",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Tech Billionaire Chase Coleman’s Top 10 Stock Picks. In this article, we are going to take a look at where Eli Lilly and Co (NYSE:LLY) stands against the other top stock picks of Tech Billionaire Chase Coleman. “Tiger cub” Chase Coleman continues to shape the investment landscape with […]",
      "url": "https://finnhub.io/api/news?id=263724c2fcf91be94375f3245aca3d38b2bb391a5984eab65cde89aec8b9a17c"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst",
    "summary": "Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets cut its price target on the pharmaceutical company from $156 to $105 per share. \"This was supposed to be Novo's answer to Tirzepatide and Retatrutide, some higher efficacy drugs, and it kind of feels like where no man's land here. So we're really focused on next year when it comes to 4Q results, that's going to set the tone for the commercial side of these products for both Lilly and Novo,\" BMO Capital Markets managing director of biopharma equity research Evan Seigerman explains. \"And then mid-year for Lilly, we have Orforglipron, which is their small molecule pill GLP-1, which could really open up the market. So I feel like Novo is kind of losing its pep a little bit,\" he goes on to say to Brad Smith and Josh Lipton. Seigerman — who maintains an Outperform rating Novo Nordisk — also comments on the impact the incoming Trump administration could have on the pharma space, particularly with Robert F. Kennedy Jr. assuming the role of secretary of the Department of Health and Human Services (HHS): \"I think the first thing he could do would be make it more challenging for Medicare to cover GLP-1s for things like heart disease and sleep apnea. That's a big hypothetical...\" To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan.",
    "url": "https://finnhub.io/api/news?id=dc451877af6528648c9f98a400db1211a380257b2ab5b236d5154b20ce503913",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735126214,
      "headline": "Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst",
      "id": 132142968,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets cut its price target on the pharmaceutical company from $156 to $105 per share. \"This was supposed to be Novo's answer to Tirzepatide and Retatrutide, some higher efficacy drugs, and it kind of feels like where no man's land here. So we're really focused on next year when it comes to 4Q results, that's going to set the tone for the commercial side of these products for both Lilly and Novo,\" BMO Capital Markets managing director of biopharma equity research Evan Seigerman explains. \"And then mid-year for Lilly, we have Orforglipron, which is their small molecule pill GLP-1, which could really open up the market. So I feel like Novo is kind of losing its pep a little bit,\" he goes on to say to Brad Smith and Josh Lipton. Seigerman — who maintains an Outperform rating Novo Nordisk — also comments on the impact the incoming Trump administration could have on the pharma space, particularly with Robert F. Kennedy Jr. assuming the role of secretary of the Department of Health and Human Services (HHS): \"I think the first thing he could do would be make it more challenging for Medicare to cover GLP-1s for things like heart disease and sleep apnea. That's a big hypothetical...\" To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan.",
      "url": "https://finnhub.io/api/news?id=dc451877af6528648c9f98a400db1211a380257b2ab5b236d5154b20ce503913"
    }
  },
  {
    "ts": null,
    "headline": "The Big Companies Funding Trump’s Inauguration Despite Denouncing Jan. 6",
    "summary": "Now, many of those companies are lining up to fund  Donald Trump’s  inauguration.  The Wall Street Journal has identified at least 11 companies and trade associations that are backing the inauguration, which is on track to be the most lucrative ever, after earlier pledging to suspend or reconsider political-action committee donations after Jan. 6.  Ford,  Intuit Toyota  and the Pharmaceutical Research and Manufacturers of America are each giving $1 million.",
    "url": "https://finnhub.io/api/news?id=2700ac93f946aa376f045caca3020d42bef82c43aabb16b9dad24436bd8c7ef5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735092000,
      "headline": "The Big Companies Funding Trump’s Inauguration Despite Denouncing Jan. 6",
      "id": 132139241,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Now, many of those companies are lining up to fund  Donald Trump’s  inauguration.  The Wall Street Journal has identified at least 11 companies and trade associations that are backing the inauguration, which is on track to be the most lucrative ever, after earlier pledging to suspend or reconsider political-action committee donations after Jan. 6.  Ford,  Intuit Toyota  and the Pharmaceutical Research and Manufacturers of America are each giving $1 million.",
      "url": "https://finnhub.io/api/news?id=2700ac93f946aa376f045caca3020d42bef82c43aabb16b9dad24436bd8c7ef5"
    }
  }
]